KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Depreciation & Amortization (CF) data on record, last reported at $145.0 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 14.72% year-over-year to $145.0 million; the TTM value through Dec 2025 reached $543.7 million, up 12.59%, while the annual FY2025 figure was $543.7 million, 12.59% up from the prior year.
  • Depreciation & Amortization (CF) reached $145.0 million in Q4 2025 per REGN's latest filing, up from $136.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $145.0 million in Q4 2025 and bottomed at $67.4 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $109.2 million, with a median of $113.0 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): increased 10.24% in 2022, then soared 38.58% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $67.4 million in 2021, then skyrocketed by 48.52% to $100.1 million in 2022, then rose by 12.89% to $113.0 million in 2023, then increased by 11.86% to $126.4 million in 2024, then increased by 14.72% to $145.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $145.0 million in Q4 2025, $136.7 million in Q3 2025, and $135.1 million in Q2 2025.